Tetraphase to Present at UBS 2010 Global Life Sciences Conference

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) gram negative pathogens, today announced that the Company will present at the UBS Global Life Science Conference on Monday, September 20, at 9:30 am ET at the Grand Hyatt Hotel, New York City.

Guy Macdonald, President and CEO of Tetraphase, will provide an overview of the Company, its strategic objectives and review its pipeline, including its lead candidate TP-434, a novel broad-spectrum intravenous (I.V.) antibiotic with potential for oral step-down capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug-resistant gram-positive, anaerobic and atypical pathogens.

A live audio webcast of this presentation can be accessed at http://cc.talkpoint.com/ubsx001/092110a_lv/?entity=155_C00CQXW. An archived presentation will be available for 90 days.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs for serious infections such as drug resistance and gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics with either broad-spectrum activity or activity more narrowly focused by indication that provide a complementary portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections. To learn more about Tetraphase, please visit www.tphase.com.



CONTACT:

Tetraphase Pharmaceuticals
David Lubner, 617-715-3551
SVP, COO

KEYWORDS:   United States  North America  Massachusetts  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.

The Big Pharma paid $134 million to enter into the two partnerships, but then dropped the projects after Voyager completed research activities.